ArticleJournal of neuro-oncology2026
Individual and community-level associations of social determinants with pituitary adenoma disparities in the US.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThrough interactional, multilevel models of social determinants of health (SDoH) incorporating comprehensive census-level and individual-level SDoH-factors, to assess whether pituitary adenoma disparities are more strongly associated with community-level factors compared to individual-level ones.
methodsThis retrospective study analyzed pituitary adenoma patients nationally between 2010 and 2018 using multivariate, age-adjusted regressions and cox-proportional hazards models; covariates of sex, race-ethnicity, census-level rurality-urbanicity, census-level Yost-Index score (aggregating 7 SES-measures of education, income, housing) and clinical outcomes of mortality, surgical resection, & delays-in-treatment (3 months-or-over from diagnosis).
resultsAcross 44,514 pituitary adenomas-patients, all-cause mortality featured markedly positive independent predictors of decreasing Yost-SES (OR, 1.43; 95% CI, 1.35-1.52; p < 0.001) and Male-Sex (OR, 1.24; 95% CI, 1.16-1.32; p < 0.001). Indicated surgery receipt showed markedly positive independent predictors of Male-Sex (OR, 1.64; 95% CI, 1.59-1.72; p < 0.001), Minority Race/Ethnicity (OR, 1.18; 95% CI, 1.14-1.23; p < 0.001), and Rurality (OR, 1.08; 95% CI, 1.01-1.16; p = 0.030). Having a delay-of-treatment showed markedly positive independent predictors of Female-Sex (OR, 1.24; 95% CI, 1.18-1.30; p < 0.001) and decreasing Yost-SES (OR, 1.14; 95% CI, 1.08-1.20; p < 0.001).
conclusionsThrough assessing individual- and community-level social determinants in tandem, this study identified detrimental SDoH-associations with pituitary adenoma care and prognosis. Community-level Yost-Index SES and individual sex showed stronger associations with observed disparities, presenting multilevel considerations for prospective initiatives to consider.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.